Medicare Implements AWP-5% Payment Rate For “Uncoded” Drugs
Executive Summary
The Centers for Medicare & Medicaid Services is implementing a provision of the 2003 Medicare law that establishes an AWP-5% payment rate for drugs covered by the Outpatient Prospective Payment System that have not yet received a reimbursement code
You may also be interested in...
Faslodex, Aranesp Have Special Status Under Hospital Payment Rule
CMS is proposing to allow separate Medicare payments for Faslodex, Trelstar and argatroban use in the hospital outpatient setting when the products become ineligible for "pass-through" payments in 2005
Faslodex, Aranesp Have Special Status Under Hospital Payment Rule
CMS is proposing to allow separate Medicare payments for Faslodex, Trelstar and argatroban use in the hospital outpatient setting when the products become ineligible for "pass-through" payments in 2005
Drug-Eluting Stents Will Be Model For CMS/FDA Cooperation – McClellan
The drug-eluting stent approval and reimbursement process should serve as a model for how CMS and FDA can work more closely together to ensure coverage for new technologies, CMS Administrator Mark McClellan told the Food & Drug Law Institute conference in Washington, D.C. April 15